“Trogarzo® represents an important niche in the fight against multidrug-resistant HIV, and our partnership with Helios Pharma brings us one step closer to ensuring that this revolutionary therapy reaches those who need it most,” said Jimmy, Chang, Ph.D., CEO of TaiMed Biologics. “At TaiMed Biologics, we are driven by a singular vision: to make Trogarzo® available to patients across the globe, where it can transform lives and provide hope. This collaboration with Helios Pharmaceutical Company marks a new chapter in our mission to expand access to life-saving therapies, and we are enthusiastic about the positive impact it will have on the healthcare landscape in Vietnam.”
About Trogarzo® (Ibalizumab-uiyk):
Trogarzo® (ibalizumab-uiyk) is a groundbreaking innovation in HIV therapy, representing the world’s first approved monoclonal antibody for HIV treatment with a long-acting effect. By targeting CD4 receptors, it acts as a post-attachment HIV-1 inhibitor, preventing viral entry into CD4+ cells. Currently, Trogarzo® is the only monoclonal antibody approved for HIV treatment. When used in combination with other antiretroviral agents, it is indicated for heavily treatment-experienced adults with multidrug-resistant (MDR) HIV-1 infection who have failed their current antiretroviral regimen.
Trogarzo® is approved by the U.S. FDA for intravenous administration via infusion or IV push (undiluted form) every two weeks. It is gradually becoming available in other countries and regions.
About TaiMed Biologics
TaiMed Biologics (4147.TWO), founded in 2007 in Taiwan, is a leading commercial-stage biotechnology company dedicated to developing innovative therapies for HIV treatment. TaiMed successfully developed ibalizumab (Trogarzo®), the first-in-class monoclonal antibody for HIV, which received U.S. FDA approval in 2018. The company is also focused on developing long-acting biologics and antibody-drug conjugates (ADC) for HIV therapy.
In addition to its R&D efforts, TaiMed offers comprehensive contract development and manufacturing (CDMO) services to pharmaceutical clients. The company has been publicly traded on the OTC Market since November 2015 and is currently part of the MSCI Small Cap Index.
About Helios Pharmaceutical Company Limited
Helios Pharma is one of the leading pharmaceutical local distributors in Vietnam. Helios Pharma is committed to advancing patient access to innovative medicines, aligning Vietnam’s healthcare system with global standards. The company strategically focuses on cutting-edge pharmaceutical solutions, ensuring that high-quality healthcare is accessible to patients across the nation.
To support its mission, Helios Pharma has developed a robust and reliable distribution network, designed to efficiently supply a diverse range of pharmaceuticals to the Vietnamese market by collaborating with the government, hospitals, and doctors to develop innovative healthcare solutions for diseases with high unmet medical needs. Learn more at www.heliospharma.vn
Contact CDMO Service